Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 8/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22127894 | 1.00 | MEN1 (0.45) | MEN1KMT2ATLR2TLR1CMA1 | |
| SCHEMBL22127891 | 1.00 | MEN1 (0.45) | MEN1KMT2ATLR2TLR1CMA1 | |
| SCHEMBL22127825 | 0.94 | KMT2A (0.43) | MEN1KMT2ATLR2TLR1CMA1 | |
| SCHEMBL22127822 | 0.94 | KMT2A (0.43) | MEN1KMT2ATLR2TLR1CMA1 | |
| SCHEMBL22127818 | 0.94 | KMT2A (0.43) | MEN1KMT2ATLR2TLR1CMA1 | |
| SCHEMBL29482134 | 0.93 | TLR2 (0.46) | MEN1KMT2ATLR2TLR1CMA1 | |
| SCHEMBL22127920 | 0.89 | TLR2 (0.43) | MEN1KMT2ATLR2TLR1CMA1 | |
| SCHEMBL22127923 | 0.89 | TLR2 (0.43) | MEN1KMT2ATLR2TLR1CMA1 | |
| SCHEMBL22127922 | 0.89 | TLR2 (0.43) | MEN1KMT2ATLR2TLR1CMA1 | |
| SCHEMBL22127854 | 0.88 | TLR2 (0.44) | MEN1KMT2ATLR2TLR1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3988561-B1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPHARMA LTD (KY) | 2023-06-07 | — | — | EP | disclosed |
| EP-3988561-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPharma Ltd. (KY) | 2022-04-27 | — | — | EP | disclosed |
| US-11312703-B2 | Reactive oxygen species scavengers and use for treating diseases | XWPharma Ltd. (KY) | 2022-04-26 | — | — | US | disclosed |
| EP-3679051-B1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPHARMA LTD (KY) | 2021-12-29 | — | — | EP | disclosed |
| US-20210061791-A1 | REACTIVE OXYGEN SPECIES SCAVENGERS AND USE FOR TREATING DISEASES | XWPharma Ltd. (KY) | 2021-03-04 | — | — | US | disclosed |
| US-10889572-B2 | Reactive oxygen species scavengers and use for treating diseases | XW LABORATORIES INC. (KY) | 2021-01-12 | — | — | US | disclosed |
| US-20200199108-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPharma Ltd. (KY) | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10889572-B2 | Reactive oxygen species scavengers and use for treating diseases | GSR, TXNRD2, GPX1 | MEN1 4367/4885KMT2A 4439/4885TLR2 3086/4885 |
| US-20210061791-A1 | REACTIVE OXYGEN SPECIES SCAVENGERS AND USE FOR TREATING DISEASES | GSR, TXNRD2, GPX1 | MEN1 4367/4885KMT2A 4439/4885TLR2 3086/4885 |
| US-20200199108-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | GPX1, SOD1, GPX4 | MEN1 4322/4885KMT2A 4630/4885TLR2 3389/4885 |
| US-11312703-B2 | Reactive oxygen species scavengers and use for treating diseases | GSR, TXNRD2, GPX1 | MEN1 4367/4885KMT2A 4439/4885TLR2 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.